Blockade of IL-23: What is in the Pipeline?

Abstract Interleukin 23 [IL-23] plays a key role in the pathogenesis of both Crohn’s disease [CD] and ulcerative colitis [UC], promoting a Th17 cell-related immune response. The combined blockade of IL-23 and IL-12 with ustekinumab has been demonstrated to be safe and effective in the treatment of i...

Full description

Saved in:
Bibliographic Details
Published in:Journal of Crohn's and colitis 2022-05, Vol.16 (Supplement_2), p.ii64-ii72
Main Authors: Parigi, Tommaso Lorenzo, Iacucci, Marietta, Ghosh, Subrata
Format: Article
Language:English
Subjects:
Colitis, Ulcerative - drug therapy
Crohn Disease - drug therapy
Crohn Disease - pathology
Humans
Inflammatory Bowel Diseases - drug therapy
Interleukin-23
Review
Ustekinumab - therapeutic use
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Interleukin 23 [IL-23] plays a key role in the pathogenesis of both Crohn’s disease [CD] and ulcerative colitis [UC], promoting a Th17 cell-related immune response. The combined blockade of IL-23 and IL-12 with ustekinumab has been demonstrated to be safe and effective in the treatment of inflammatory bowel disease [IBD]. Studies on preclinical models and observations of other immune-mediated diseases, such as psoriasis, suggest that the selective inhibition of IL-23 could be beneficial in IBD. Four monoclonal antibodies [risankizumab, mirikizumab, brazikumab and guselkumab] are currently in advance clinical trials for either CD or UC. In this review, we provide an overview of the main results from published studies of selective anti IL-23 agents.
ISSN:1873-9946
1876-4479
1876-4479
DOI:10.1093/ecco-jcc/jjab185